The Problem of Cancer Immunotherapy in Perspective

  • O. J. Plescia
  • A. Smith
  • K. Grinwich
  • C. Feit


The basic premises underlying cancer immunotherapy are (a) that cancer cells possess cancer-specific transplantation-like antigens, and (b) that their host is capable of mounting an immune response to these antigens that results in the rejection of the cancer cells as a homograft.


Antibody Response Spleen Cell Cancer Immunotherapy Prostaglandin Synthetase Syngeneic Tumor 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Braun, W. Cyclic AMP changes as a consequence of tumor-normal cell interactions. In Braun, W., Lichtenstein, L., and Parker, C, eds. Cyclic AMP, Cell Growth and the Immune Response, New York, Springer-Verlag, 1974, pp. 349–357.Google Scholar
  2. 2.
    Humes, J. and Strausser, H. Prostaglandins and cyclic nucleotides in Maloney sarcoma tumors. Prostaglandins, 5:183, 1974.CrossRefGoogle Scholar
  3. 3.
    Jerne, N. K., Nordin, A. A., and Henry, C. In Amos, B. and Koprowski, H., eds. Cell Bound Antibodies, Philadelphia; Wistar Institute Press, 1963, pp. 109–116.Google Scholar
  4. 4.
    Klein, G. Experimental studies in tumor immunology. Fed. Proc, 28:1739, 1969.Google Scholar
  5. 5.
    Melmon, K., Bourne, H., Weinstein, Y., Shearer, G., Kram, J., and Bauminger, S. Hemolytic plaque formation by leukocytes in vitro. J. Clin. Invest., 53:13, 1974.PubMedCrossRefGoogle Scholar
  6. 6.
    Plescia, O. J. Tumor-specific antigens: Relationship to immunotherapy and etiology of cancer. In Ceglowski, W. and Friedman, H., eds. Virus Tumorigenesis and Immuno-genesis. New York, Academic Press, 1973, pp. 1–30.Google Scholar
  7. 7.
    Plescia, O. J., Yamamoto, I., Shimamura, T., and Feit, C. Early cellular events in the response of mice to sheep red blood cells reflected by changes in the spleen level of cyclic AMP. Ann. N.Y. Acad. Sci., 249:362,1975.PubMedCrossRefGoogle Scholar
  8. 8.
    Sykes, J. and Maddox, I., Prostaglandin production by experimental tumors and effects of anti-inflammatory compounds. Nature [New Biol.], 237:59, 1972.Google Scholar
  9. 9.
    Tashjian, A., Voelkel, E., Levine, L., and Goldhaber, P. Evidence that the bone resorption-stimulating factor produced by mouse fibrosarcoma cells is prostaglandin E2. J. Exp. Med., 136:1329, 1972.PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag New York Inc. 1975

Authors and Affiliations

  • O. J. Plescia
  • A. Smith
  • K. Grinwich
  • C. Feit

There are no affiliations available

Personalised recommendations